These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A proposal for radical changes in the drug-approval process. Wood AJ N Engl J Med; 2006 Aug; 355(6):618-23. PubMed ID: 16899784 [No Abstract] [Full Text] [Related]
3. The FDA's drug review process: ensuring drugs are safe and effective. Meadows M FDA Consum; 2002; 36(4):19-24. PubMed ID: 12184298 [No Abstract] [Full Text] [Related]
4. Two-stage drug approval would reduce the risks. Frantz JA Nature; 2005 May; 435(7039):143. PubMed ID: 15889063 [No Abstract] [Full Text] [Related]
6. Real-world evidence-What is it and does it matter for approval of drugs? Eaglstein WH J Am Acad Dermatol; 2018 Aug; 79(2):390-391. PubMed ID: 29410344 [No Abstract] [Full Text] [Related]
7. Does neurology need a faster FDA? Burton A Lancet Neurol; 2014 Aug; 13(8):760-1. PubMed ID: 25030510 [No Abstract] [Full Text] [Related]
8. Drugs with FDA accelerated approval often have weak evidence, study finds. Dyer O BMJ; 2017 Jun; 357():j2905. PubMed ID: 28615167 [No Abstract] [Full Text] [Related]
9. Accelerated approval of oncology drugs: can we do better? Ellenberg SS J Natl Cancer Inst; 2011 Apr; 103(8):616-7. PubMed ID: 21422401 [No Abstract] [Full Text] [Related]
10. US Food and Drug Administration and design of drug approval studies. Woloshin S; Schwartz LM; Frankel B; Faerber A JAMA; 2014 Nov; 312(20):2163-5. PubMed ID: 25423223 [No Abstract] [Full Text] [Related]
11. Drugs with breakthrough status charm investors. Senior M Nat Biotechnol; 2013 Nov; 31(11):945-7. PubMed ID: 24213748 [No Abstract] [Full Text] [Related]
12. Errors in 'Trials and error'. Miller DD Nat Biotechnol; 2006 Jul; 24(7):747. PubMed ID: 16841048 [No Abstract] [Full Text] [Related]
13. Swimming upstream: an advocate reflects on cancer research and social realities. Mayer M J Clin Oncol; 2008 Jun; 26(16):2783-6. PubMed ID: 18509190 [No Abstract] [Full Text] [Related]
15. Letter from the Commissioner's Office at the US FDA. Vernon JA Pharmacoeconomics; 2007; 25(4):267-8. PubMed ID: 17402801 [No Abstract] [Full Text] [Related]
16. Conflating the approval process and clinical research with pharmacoeconomic evaluation. Somberg JC Am J Ther; 2013 Jan; 20(1):1. PubMed ID: 23299228 [No Abstract] [Full Text] [Related]
17. Early accelerated approval for highly targeted cancer drugs. Chabner BA N Engl J Med; 2011 Mar; 364(12):1087-9. PubMed ID: 21428763 [No Abstract] [Full Text] [Related]
18. New fee structure proposed by FDA might lead to more talk. Waters H Nat Med; 2011 Oct; 17(10):1159. PubMed ID: 21988966 [No Abstract] [Full Text] [Related]
19. A critical tipping point. Zuckerman MB US News World Rep; 2002 Apr; 132(13):72. PubMed ID: 11993366 [No Abstract] [Full Text] [Related]
20. Allen D. Rose. Rose AD Nat Rev Drug Discov; 2004 May; 3(5):382. PubMed ID: 15152630 [No Abstract] [Full Text] [Related] [Next] [New Search]